---
title: 'Executive Director, Marketing at IMVT Corporation'
canonical: 'https://feeny.ai/job/executive-director-marketing-imvt-corporation-remote-sc5ja0w76sbv'
type: 'job'
last_seen: '2026-10-30'
---

# Executive Director, Marketing at IMVT Corporation

- **Company:** IMVT Corporation
- **Location:** Remote
- **Compensation:** $280k–$320k
- **Work type:** remote
- **Posted:** 2026-10-29
- **Last confirmed live:** 2026-10-30
- **Apply:** https://job-boards.greenhouse.io/imvtcorporation/jobs/6238295004

## Job description

Immunovant, Inc. is a clinical-stage biopharmaceutical company dedicated to enabling normal lives for people with autoimmune diseases. As trailblazers in FcRn inhibitor technology, the Company is boldly developing innovative therapies for a range of debilitating autoimmune diseases with significant unmet patient needs.

The Role:

The Executive Director of Marketing is critical to the commercial launch of IMVT-1402 and the company's transition from clinical-stage to commercial-stage.  Reporting to the General Manager of Commercial, this position leads the definition and establishment of the marketing strategy for all IMVT-1402 indications (Graves, MG, and others in development).  Partnering with their team, the Executive Director will also work to ensure launch readiness and launch execution.

Key Responsibilities:

Marketing

- Lead the development of an insight-driven marketing strategy and positioning for each brand indication by applying a strategic framework that uses key leverage points and strategic choices to determine targeting scenarios.
- Lead a cross-functional team, build and shape all launch plans to ensure organizational readiness and success
- Partner with Business Analytics to ensure a robust market research plan to deliver market insights for each indication and competitive intelligence and positioning as integral components of indication-level strategic and tactical plans as well as forecast assumptions. Contribute to forecast-level assumptions and analytics.
- Review indication-level campaigns and tactics to ensure alignment to the brand strategic choices and key leverage points. Ensure alignment with product positioning and messaging across targeted HCP and consumer tactics while maintaining a high standard of quality and compliance for Immunovant.
- Develop a disease education campaign to shape the market for a new entrant and catalyze a change in Graves’ Disease understanding and treatment approach and determine requirements for similar campaigns in follow-on indications.
- Ensure brand/launch strategies and positioning are reflected in promotional materials for key customer segments (e.g., HCPs, patients, KOLs, allied health professionals, market access stakeholders) and across multiple channels.
- Establish media campaigns to support the indications, inclusive of the multi-channel specific strategies and tactics necessary to support the Customer Engagement team e.g., face-to-face, digital, CRM, etc.
- Regularly engage with and support the need for thought partnership with functional partners (sales, market access, distribution, medical affairs, etc..).
- Communicate with the organization regarding marketing strategy and commercial readiness.
- Maintain expertise in each disease state, competitive landscape, and market dynamics, informing potential pivots in strategic and executional approach as needed.
- Responsible for the management of the marketing team, P&L by indication, and budget.

Requirements:

- BA/BS required; MBA and/or other relevant graduate degree preferred
- 12+ years of marketing experience in a biotechnology or pharmaceutical organization. Launch experience required
- Track record of enterprise and executive leadership influence - able to lead through ambiguity, align diverse stakeholders, and drive decisions across functions outside of direct reporting lines.
- Exceptional communication skills; able to synthesize complex inputs into clear recommendations for executive leadership.
- Demonstrated analytical and problem-solving skills, leading to the development of innovative marketing initiatives.
- Analytical, creative, solution-oriented, and decisive.

Work Environment:

- Remote; Available for travel to Immunovant’s NYC office as requested
- Dynamic, interactive, fast-paced, and entrepreneurial environment
- Domestic or international travel is required (up to 20%)

Salary range for posting $280,000—$320,000 USD

Compensation is based on a number of factors, including market location, and may vary depending on job-related knowledge, skills, and experience. Equity and other forms of compensation may be provided as part of a total compensation package, in addition to a full range of medical, dental, vision, 401k, and other benefits, including unlimited paid time off and parental leave.

## About IMVT Corporation

## Company Overview
- **One-liner**: A clinical-stage immunology company developing innovative anti-FcRn therapies to enable normal lives for people with autoimmune diseases.
- **Entity Type**: Public (Nasdaq: IMVT)
- **Headquarters**: Durham, North Carolina, United States
- **Founded**: Not publicly available
- **Founders**: Not publicly available

## Core Business
- **Primary industry**: Biotechnology / Autoimmune disease therapeutics
- **Target customers**: Patients with IgG-mediated autoimmune diseases; healthcare providers; payers (B2B/B2C mix via prescription drugs)
- **Mission or purpose statement**: “Dedicated to enabling normal lives for people with autoimmune diseases” [immunovant.com](https://www.immunovant.com/)

## Products & Services
- **[IMVT-1402 (imeroprubart)]**: A novel, fully human monoclonal antibody that targets FcRn to reduce pathogenic IgG autoantibodies. Designed as a subcutaneous injection with a simple autoinjector (YpsoMate®). In clinical development for six indications: Graves’ disease (GD), difficult-to-treat rheumatoid arthritis (D2T RA), myasthenia gravis (MG), chronic inflammatory demyelinating polyneuropathy (CIDP), Sjögren’s disease (SjD), and cutaneous lupus erythematosus (CLE). [10-K (2026)](https://www.immunovant.com/investors/sec-filings/all-sec-filings/content/0001764013-26-000064/0001764013-26-000064.pdf)
- **[Batoclimab (first-generation anti-FcRn)]**: Development discontinued across all indications after Phase 3 TED trials did not meet primary endpoints; learnings inform IMVT-1402 program. [10-K (2026)](https://www.immunovant.com/investors/sec-filings/all-sec-filings/content/0001764013-26-000064/0001764013-26-000064.pdf)

## Market Standing
- **Valuation/Market Cap**: Not disclosed in available sources (publicly traded on Nasdaq; refer to real-time market data).
- **Key Metric**: Clinical-stage company with no approved products or revenue; total funding and operating expenses are detailed in SEC filings but not summarized here.
- **Notable Investors/Partners**: HanAll Biopharma (collaboration on anti-FcRn antibodies); Ypsomed AG (auto-injector YpsoMate®). [10-K (2026)](https://www.immunovant.com/investors/sec-filings/all-sec-filings/content/0001764013-26-000064/0001764013-26-000064.pdf)
- **Growth Signals**: Six ongoing clinical programs (including potentially registrational trials); deep IgG reductions (~80% with weekly 600 mg IMVT-1402) suggesting best-in-class potential; Phase 1 safety data showing no/minimal albumin reduction or LDL cholesterol increases. [10-K (2026)](https://www.immunovant.com/investors/sec-filings/all-sec-filings/content/0001764013-26-000064/0001764013-26-000064.pdf)

## Competitive Advantages
- **Potential best-in-class efficacy**: IMVT-1402 achieves deeper IgG reductions than competitor anti-FcRn antibodies, correlating with improved clinical outcomes.
- **Favorable safety profile**: No or minimal off-target effects on albumin and LDL cholesterol, unlike some FcRn inhibitors.
- **Convenient administration**: Self-administered subcutaneous autoinjector (YpsoMate®) expected at launch, improving patient adherence.
- **Broad pipeline**: Six indications in development across endocrinology, rheumatology, neurology, and dermatology, with potential for more.

## Strategic Focus
- Execute pivotal trials for IMVT-1402 in GD, D2T RA, MG, CIDP, SjD, and CLE.
- Leverage learnings from batoclimab program to accelerate IMVT-1402 development.
- Plan to assess new indications for IMVT-1402 beyond the initial six.
- Continue to build commercial capabilities for eventual launch. [10-K (2026)](https://www.immunovant.com/investors/sec-filings/all-sec-filings/content/0001764013-26-000064/0001764013-26-000064.pdf)

## Why Work Here
- **Culture**: Emphasizes “Hire and Retain Only the Very Best,” “One Team, Shared Success,” “Ownership Mentality,” and “Patients Are Waiting” – a mission-driven, high-performance environment. [About Us](https://www.immunovant.com/about-us)
- **Remote/Hybrid Policy**: Job listings show a mix of remote and hybrid roles (e.g., “Remote” for many positions, “Hybrid - NYC” for commercial roles). [Careers](https://www.immunovant.com/join-us/explore-careers)
- **Notable Perks**: Merit-based recognition, focus on impact and results, creative problem-solving encouraged. [About Us](https://www.immunovant.com/about-us)
- **Engineering/Science Culture**: Clinical-stage biotech with cutting-edge FcRn technology; opportunities in clinical development, biometrics, quality assurance, and commercial roles. [Careers](https://www.immunovant.com/join-us/explore-careers)

## Sources
1. [Immunovant Corporate Website](https://www.immunovant.com/)
2. [About Us – Values and Culture](https://www.immunovant.com/about-us)
3. [Company Information – Investor Relations](https://www.immunovant.com/investors/company-information)
4. [Explore Careers – Job Listings](https://www.immunovant.com/join-us/explore-careers)
5. [10-K SEC Filing (May 20, 2026)](https://www.immunovant.com/investors/sec-filings/all-sec-filings/content/0001764013-26-000064/0001764013-26-000064.pdf)

## Other roles at IMVT Corporation

- [Associate Director, Biostatistics](https://feeny.ai/job/associate-director-biostatistics-imvt-corporation-remote-dgj2yvz4mm9k)
- [Senior Manager, Medical Communications](https://feeny.ai/job/senior-manager-medical-communications-imvt-corporation-remote-s03pz93xa8tp)
- [Executive Director, New Product Planning](https://feeny.ai/job/executive-director-new-product-planning-imvt-corporation-remote-hek53s90egtb)
- [Director, Infrastructure & Data Platforms](https://feeny.ai/job/director-infrastructure-data-platforms-imvt-corporation-remote-vcb6ytpndm32)
- [Director, Supply Chain Product Planning](https://feeny.ai/job/director-supply-chain-product-planning-imvt-corporation-remote-a4ek4z6agfre)
- [Senior Director, Corporate & Commercial IT Business Systems](https://feeny.ai/job/senior-director-corporate-commercial-it-business-systems-imvt-corporation-remote-vw2vm2e990w9)
- [Senior Manager, Statistical Programming](https://feeny.ai/job/senior-manager-statistical-programming-imvt-corporation-remote-6q5z9h7nwxvn)
- [Director, Financial Planning & Analysis](https://feeny.ai/job/director-financial-planning-analysis-imvt-corporation-remote-2xtk0zhd4zbr)
- [Executive Assistant](https://feeny.ai/job/executive-assistant-imvt-corporation-new-york-m7dv0wr8rkjs) — New York, NY
- [Director, Medical Science Liaison (MSL)](https://feeny.ai/job/director-medical-science-liaison-msl-imvt-corporation-southeast-cnykwbftkpjw) — Southeast, United States